Treatment Resistant Depression 

The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone (ClinicalTrals.gov, 2019)

18-65

III

NCT03739203

Age Group

Phase

Clinical Trial #

Traumatic Brain Injury (TBI)

This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury (TBI) (ClinicalTrials.gov, 2020).

18-75

II

NCT03095066

Age Group

Phase

Clinical Trial #

Binge Eating Disorder (BED)

This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury (TBI) (ClinicalTrials.gov, 2020).

18-55

II

NCT

Age Group

Phase

Clinical Trial #

Endometriosis

The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis. (ClinicalTrials.gov, 2019)

18-49

II

 NCT03840993

Age Group

Phase

Clinical Trial #

Post Traumatic Stress Disorder

This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder. (ClinicalTrials.gov, 2019)

18-65

III

NCT04174170

Age Group

Phase

Clinical Trial #

Tourette Syndrome

To evaluate the long-term efficacy of oral aripiprazole in pediatric subjects for the treatment of Tourette's Disorder (TD) (ClinicalTrials.gov, 2019)

6-17

IIII

NCT03661983

Age Group

Phase

Clinical Trial #

Negative Symptoms of Schizophrenia

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia (ClinicalTrials.gov, 2020)

18-60

III

NCT03896945

Age Group

Phase

Clinical Trial #

P. 440.234.5700
F. 440.234.5710
info@northstarresearch.org
 
18660 Bagley Road, Building II, Suite 205 Middleburg Heights, OH 44130
  • White Facebook Icon
  • White Instagram Icon
  • White YouTube Icon

© 2019 North Star Medical in corporation with Wix.com